Skin care compositions and uses thereof

Abstract

The present application discloses a skin care composition and its use, the skin care composition comprises ectoine and raspberry ketone, the mass ratio of the ectoine and raspberry ketone is 10:1~1:15, the skin care composition has a positive effect on promoting skin barrier repair.

Description

Technical Field

[0001] This application relates to the field of cosmetic technology, and more particularly to a skin care composition and its use. Background Technology

[0002] When the skin barrier is damaged (such as in sensitive skin, atopic dermatitis, acne, etc.), it is necessary to rebuild a complete physical and immune barrier. This is mainly achieved by accelerating the formation of the epidermal barrier, promoting the maturation of epidermal function, and inhibiting the inflammatory response of the skin.

[0003] Peroxisome proliferator-activated receptors (PPARs) regulate various intracellular metabolic processes. PPARs include three subtypes: PPARα, PPARβ / δ, and PPARγ. PPARα plays a crucial role in skin barrier repair, and promoting its expression is beneficial for barrier recovery in consumers with thin skin, seasonal sensitivity, and those prone to symptoms such as redness, swelling, and itching.

[0004] TNF-α is a pro-inflammatory cytokine primarily produced by macrophages and monocytes. It can stimulate the release of other inflammatory factors, exacerbating the inflammatory response and leading to symptoms such as redness, swelling, pain, and itching. Simultaneously, it may impair the skin barrier function, making the skin more susceptible to external stimuli and causing problems such as sensitivity, dryness, and flaking. Overexpression of TNF-α may also worsen barrier damage, promoting the exacerbation of acne inflammation and intensifying redness and swelling in rosacea.

[0005] Raspberry ketone can promote the expression of peroxisome proliferator-activated receptors (PPARs) and inhibit the expression of inflammatory factors, thereby repairing the damaged skin barrier. However, the recommended dosage of raspberry ketone in cosmetics is low. How to achieve similar or better effects while reducing its dosage is a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0006] The inventors of this application unexpectedly discovered that, at the same dosage, both ectoine and raspberry ketone have different degrees of effects in promoting the expression of peroxisome proliferator-activated receptors (PPARs) and inhibiting the expression of inflammatory factors, and that the effect of raspberry ketone is better than that of ectoine.

[0007] Further analysis of the two substances in a specific ratio revealed that the combined substance could achieve similar or better effects than higher amounts of raspberry ketone with a smaller amount of raspberry ketone, thus completing the present invention.

[0008] The specific technical solution of this application is as follows:

[0009] 1. A skin care composition comprising ectoine and raspberry ketone, wherein the mass ratio of ectoine to raspberry ketone is 10:1 to 1:15.

[0010] 2. The skin care composition according to item 1, wherein the mass ratio of ectoine to raspberry ketone is 1:4 to 12.

[0011] 3. The skin care composition according to any one of items 1-2, wherein the skin care composition further comprises excipients acceptable for skin care products.

[0012] 4. The use of the skin care composition according to any one of items 1-3 as a promoter of peroxisome proliferator-activated receptor (PPAR) expression and / or as an inhibitor of inflammatory factor expression.

[0013] 5. The use according to item 4, wherein the peroxisome proliferator-activated receptor is PPAR-α, and the inflammatory factor is TNF-α.

[0014] 6. The composition is used to promote skin barrier repair according to the use described in item 4 or 5.

[0015] 7. According to the use described in item 6, the promotion of skin barrier repair includes promoting skin barrier repair in individuals with thin skin, seasonal sensitivity, and / or those prone to redness, swelling, and itching.

[0016] 8. Use of ectoine as a promoter of peroxisome proliferator-activated receptor (PPAR) expression.

[0017] 9. The use according to item 8, wherein the peroxisome proliferator-activated receptor is PPAR-α.

[0018] 10. According to the use described in item 8 or 9, the ectoine is used to promote skin barrier repair, preferably, the promotion of skin barrier repair includes promoting skin barrier repair in people with thin skin, seasonal sensitivity and / or prone to redness, swelling and itching.

[0019] The effects of the invention

[0020] Ectoin or raspberry ketone can promote the expression of peroxisome proliferator-activated receptors (PPARs) and inhibit the expression of inflammatory factors, thereby promoting skin barrier repair. In particular, it has a good effect on skin barrier repair for people with thin skin, seasonal sensitivity and / or those prone to redness, swelling and itching.

[0021] Furthermore, the combination of ectoine and raspberry ketone can achieve similar or better effects than raspberry ketone alone. Attached Figure Description

[0022] Figure 1 This is a bar chart showing the relative expression levels of the PPAR-α gene.

[0023] Figure 2 This is a bar chart showing the relative expression levels of the TNF-α gene. Detailed Implementation

[0024] The embodiments described below provide a detailed description of this application. While specific embodiments of this application are shown, it should be understood that this application can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided to enable a more thorough understanding of this application and to fully convey the scope of this application to those skilled in the art.

[0025] It should be noted that certain terms are used in the specification and claims to refer to specific components. Those skilled in the art will understand that different terms may be used to refer to the same component. This specification and claims do not distinguish components based on differences in terminology, but rather on differences in function. The terms "comprising" or "including" used throughout the specification and claims are open-ended and should be interpreted as "comprising but not limited to." The following descriptions in the specification are preferred embodiments for carrying out this application; however, these descriptions are for the purpose of understanding the general principles of the specification and are not intended to limit the scope of this application. The scope of protection of this application shall be determined by the appended claims.

[0026] Composition

[0027] One aspect of this application relates to compositions, which are any compositions capable of achieving the effects described in this application. The compositions include, but are not limited to, the simultaneous or sequential use of the components. "Simultaneous use" includes using them together in the same formulation or separately in different formulations. "Sequential use" includes using them sequentially in different formulations, with no restriction on the order of sequential use.

[0028] This application provides a skin care composition comprising ectoine and raspberry ketone, wherein the mass ratio of ectoine to raspberry ketone is 10:1 to 1:15, preferably 1:4 to 12.

[0029] In this application, ectoin (also known as tetrahydropyrimidine carboxylic acid) is an amino acid derivative. Ectoin is derived from the halophilic bacterium *Halomonas elongata*, and is therefore also referred to as "halophilic bacterium extract". Under extreme conditions of high salt, high temperature, and high ultraviolet radiation, ectoin protects the halophilic bacteria from harm.

[0030] In this application, raspberry ketone, also known as scutellarin ketone, is an organic compound with the molecular formula C. 10 H 12 O2, molecular weight 164.22.

[0031] In this application, the mass ratio of ectoine to raspberry ketone (m 依克多因 :m 覆盆子酮 The ratios can be 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, 1:12, 1:13, 1:14, 1:15, etc.

[0032] In some embodiments, the composition further comprises excipients acceptable for use in skincare products.

[0033] This application does not impose any restrictions on the excipients described, which are excipients commonly used in the art.

[0034] The skincare composition described in this application can promote the relative expression of peroxisome proliferator-activated receptors (PPARs) and reduce the relative expression of inflammatory factors, indicating that the composition described in this application has a positive effect on the repair of skin barrier damage.

[0035] In some embodiments, the peroxisome proliferator-activated receptor is PPAR-α, and the inflammatory factor is TNF-α.

[0036] In some embodiments, the skincare composition described in this application is used to promote skin barrier repair.

[0037] In some implementations, promoting skin barrier repair includes promoting skin barrier repair in individuals with thin skin, seasonal sensitivity, and / or those prone to redness, swelling, and itching.

[0038] In some embodiments, the skincare composition described in this application is used to promote keratinocyte differentiation, promote epidermal lipid synthesis, regulate inflammatory responses, promote collagen production, reduce the formation of reactive oxygen species induced by ultraviolet radiation, and prevent ultraviolet damage.

[0039] This application also provides the use of ectoine as a promoter of peroxisome proliferator-activated receptor (PPAR) expression.

[0040] This application also provides the use of raspberry ketone as a promoter of peroxisome proliferator-activated receptor (PPAR) expression.

[0041] In some embodiments, the peroxisome proliferator-activated receptor is PPAR-α, and the inflammatory factor is TNF-α.

[0042] In some implementations, the ectoine is used to promote skin barrier repair.

[0043] In some implementations, promoting skin barrier repair includes promoting skin barrier repair in individuals with thin skin, seasonal sensitivity, and / or those prone to redness, swelling, and itching.

[0044] In some implementations, promoting skin barrier repair includes promoting skin barrier repair in individuals with thin skin, seasonal sensitivity, and / or those prone to redness, swelling, and itching.

[0045] In some embodiments, the skincare composition described in this application is used to promote keratinocyte differentiation, promote epidermal lipid synthesis, regulate inflammatory responses, promote collagen production, reduce the formation of reactive oxygen species induced by ultraviolet radiation, and prevent ultraviolet damage.

[0046] Example

[0047] This application provides a general and / or specific description of the materials and experimental methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., weight percentage. Reagents or instruments used, unless otherwise specified, are all commercially available conventional reagent products. The experimental materials used in the preparation and experimental examples are shown in Table 1, and the experimental equipment is shown in Table 2.

[0048] Table 1 shows the experimental materials used in the preparation and experimental examples.

[0049]

[0050] Table 2. List of experimental equipment used in the preparation and experimental examples.

[0051] Main equipment Manufacturer & Model Clean bench Suzhou Sujing Purification Technology Co., Ltd., SW-CJ-2D Inverted microscope OLYMPUS, CKX53 Precision electronic balance OHAUS, CP214 <![CDATA[CO2 Incubator]]> Thermo, 3111 Ultraviolet light therapy device Kono Medical Instruments & Equipment Co., Ltd., KN-4006BL1 ELISA reader Tecan, SPARK Real-time PCR instrument BioRad, CFX Connect

[0052] Preparation Example

[0053] 1. Prepare complete culture medium solution

[0054] DMEM basal culture medium, FBS fetal bovine serum, and PS double antibody solution were mixed at a mass ratio of 89:10:1.

[0055] 2. Preparation of sample groups

[0056] Weigh out ectoine and raspberry ketone powders and dissolve them in a complete culture medium solution to form the working solution of the test substance. The concentrations of ectoine and raspberry ketone are shown in Table 3, numbered 1-11.

[0057] 3. Prepare a positive control group

[0058] Weigh out the positive control drug WY-14643 and dissolve it in the complete culture medium solution to form the working solution of the test substance. The concentration of WY-14643 is shown in Table 3.

[0059] 4. Prepare blank control group and negative control group.

[0060] The blank control group and negative control group were composed of complete culture medium solutions.

[0061] Table 3. Mass ratio and corresponding concentration of ectoine and raspberry ketone

[0062] case Mass ratio of ectoine to raspberry ketone Test substance working fluid Blank control (BC) / / Negative control (NC) / / Positive control (PC) / 10μM WY-14643 1 1:0 600 μg / mL Ectocin 2 0:1 600 μg / mL raspberry ketone 3 20:1 571 μg / mL ectoine; 29 μg / mL raspberry ketone 4 9:1 540 μg / mL ectoine; 60 μg / mL raspberry ketone 5 1.5:1 360 μg / mL ectoine; 240 μg / mL raspberry ketone 6 1:1 300 μg / mL ectoine; 300 μg / mL raspberry ketone 7 1:2.5 171 μg / mL ectoine; 429 μg / mL raspberry ketone 8 1:4 120 μg / mL ectoine; 480 μg / mL raspberry ketone 9 1:9 60 μg / mL ectoine; 540 μg / mL raspberry ketone 10 1:12 46 μg / mL ectoine; 554 μg / mL raspberry ketone 11 1:20 29 μg / mL ectoine; 571 μg / mL raspberry ketone

[0063] Example 1: Determination of the relative expression level of PPAR-α

[0064] 1) Cell seeding: at 6 × 10 5 Keratinocytes were seeded into 6-well plates at a seeding density of cells / well and incubated in an incubator (37°C, 5% CO2) for 24 hours.

[0065] 2) Solution preparation: Prepare working solutions of the test substances according to the test plan (Table 3).

[0066] 3) Modeling: According to the experimental grouping, the sample group, positive control group, and negative control group were exposed to ultraviolet light therapy (wavelength 280-320nm, 80mJ / cm²). 2 UVB irradiation was performed, while the blank control group received no treatment.

[0067] 4) Drug administration: Following the test protocol in Table 3, administer the drug to the appropriate groups, adding 1 mL of sample to each well, with 3 replicates per group. After drug administration, incubate the 6-well plate in an incubator (37℃, 5% CO2) for 24 hours.

[0068] 5) Cell collection: After culturing for 24 hours, collect the cell supernatant, wash twice with 1 mL / well D'Hanks buffer, lyse the cells by pipetting, and collect the sample.

[0069] 6) Gene expression detection: After treating cells with the RNA-Quick Purification Kit, samples were collected. RNA extraction, reverse transcription, and quantitative real-time PCR were performed according to the kit instructions. 2- △△Ct The method calculates the results and obtains the detection results, which are shown in Table 4.

[0070] 7) Statistical analysis of results: The t-test was used for comparisons between groups, with a confidence level of 95%. The results are as follows: Figure 1 As shown, when the two sets of results have completely different letters, it indicates that there is a statistically significant difference between the two sets of results. When the letters of the two sets of results are exactly the same, it indicates that there is no statistical difference between the two sets. The same applies below.

[0071] Example 2: Determination of the relative expression level of TNF-α

[0072] 1) Cell seeding: at 6 × 10 5 Keratinocytes were seeded into 6-well plates at a seeding density of cells / well and incubated in an incubator (37°C, 5% CO2) for 24 hours.

[0073] 2) Solution preparation: Prepare working solutions of the test substances according to the test plan (Table 3).

[0074] 3) Modeling: According to the experimental grouping, the sample group, positive control group, and negative control group were exposed to ultraviolet light therapy (wavelength 280-320nm, 80mJ / cm²). 2 UVB irradiation was performed, while the blank control group received no treatment.

[0075] 4) Drug administration: Following the test protocol in Table 3, administer the drug to the appropriate groups, adding 1 mL of sample to each well, with 3 replicates per group. After drug administration, incubate the 6-well plate in an incubator (37℃, 5% CO2) for 24 hours.

[0076] 5) Cell collection: After culturing for 24 hours, collect the cell supernatant, wash twice with 1 mL / well D'Hanks buffer, lyse the cells by pipetting, and collect the sample.

[0077] 6) Gene expression detection: After treating cells with the RNA-Quick Purification Kit, samples were collected. RNA extraction, reverse transcription, and quantitative real-time PCR were performed according to the kit instructions. 2- △△Ct The method calculates the results and obtains the detection results, which are shown in Table 4.

[0078] 7) Statistical analysis of results: The t-test was used for comparisons between groups, with a confidence level of 95%. The results are as follows: Figure 2 As shown.

[0079] Table 4. Relative expression levels of PPAR-α and TNF-α

[0080]

[0081]

[0082] The above description is merely a preferred embodiment of this application and is not intended to limit the application in any other way. Any person skilled in the art may make changes or modifications to the disclosed technical content to create equivalent embodiments. However, any simple modifications, equivalent changes, and modifications made to the above embodiments based on the technical essence of this application without departing from the scope of the technical solution of this application shall still fall within the protection scope of this application.

Claims

1. A skin care composition comprising ectoine and rubusoside at a mass ratio of 1 :4-12.

2. The skin care composition of claim 1, wherein, The skin care composition further comprises a skin care acceptable adjuvant.

3. Use of the skin care composition according to any one of claims 1-2 for the manufacture of an article for promoting skin barrier repair.

4. The use according to claim 3, wherein the promoting skin barrier repair comprises promoting skin barrier repair in people with weak skin condition, seasonal sensitivity and / or prone to redness, itchiness.

Images